DOCSLIB.ORG

Proopiomelanocortin, a Polypeptide Precursor with Multiple Functions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proopiomelanocortin, a Polypeptide Precursor with Multiple Functions European Journal of Endocrinology (2003) 149 79–90 ISSN 0804-4643 INVITED REVIEW Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions M L Raffin-Sanson1,3, Y de Keyzer1 and X Bertagna1,2 1Institut Cochin, De´partement d’Endocrinologie, Universite´ Rene´ Descartes-Paris V, France, 2Service des Maladies Endocriniennes et Me´taboliques, Hoˆpital Cochin, Paris, France and 3Me´decine Interne 2, Endocrinologie, Hoˆpital Ambroise Pare´, Boulogne/S, France (Correspondence should be addressed to X Bertagna; Email: [email protected]) Abstract Proopiomelanocortin (POMC) is the polypeptide precursor of ACTH. First discovered in anterior pitu- itary corticotroph cells, it has more recently been revealed to have many other physiological aspects. The fine molecular mechanisms of ACTH biosynthesis show that ACTH is but one piece of a puzzle which contains many other peptides. Present in various tissues, among which are pituitary, hypo- thalamus, central nervous system and skin, POMC undergoes extensive post-translational processing. This processing is tissue-specific and generates, depending on the case, various sets of peptides involved in completely diverse biological functions. POMC expressed in corticotroph cells of the pitu- itary is necessary for adrenal function. Recent developments have shown that POMC-expressing neur- ons in the brain play a major role in the control of pain and energy homeostasis. Local production of POMC-derived peptides in skin may influence melanogenesis. A still unknown function in the placenta is likely. POMC has become a paradigmatic polypeptide precursor model illustrating the variable roles of a single gene and its various products in different localities. European Journal of Endocrinology 149 79–90 Discovering proopiomelanocortin cell line, which is derived from an irradiation-induced (POMC) mouse pituitary tumour and selectively produces and secretes large amounts of ACTH, proved to be an The era of precursors of polypeptide hormones really invaluable tool. The latter technique indeed established started in the late 1960s with the discovery and that the small peptides that were identified (the end- characterisation of two prototypes: proinsulin, the products of the precursor processing, i.e. ACTH) were precursor to insulin, by Steiner in Chicago (1), and not mere degradation products generated during the the lipotrophins (b- and gLPH), the precursors to extraction procedure, since they were not obtained b-melanocyte-stimulating hormone (bMSH) by Li after the cells had been submitted to only short pulses and Chre´tien in San Francisco (2). Clues that a of labelling. These studies therefore showed that the precursor to adrenocorticotrophin (ACTH) might HMW ACTH precursor ultimately generated a material also exist came from the work of Yalow & Berson that was physically and immunologically indistinguish- (3) who found a high molecular weight (HMW) able from ACTH (4). Later, the same biochemical immunoreactive (IR) ACTH material in the extracts studies showed that labelled amino acids incorporated of a human thymic tumour responsible for a case into the HMW ACTH precursor were immunoprecipi- of ectopic ACTH syndrome. This biologically inactive tated by anti-ACTH but also by anti-bLPH and anti- molecule released bioactive ACTH under mild diges- bendorphin (bend) antibodies (5). Thus the precursor tion by trypsin. From these premisses the search for to ACTH also seemed to contain LPH sequences as an ACTH precursor was launched. well, an explanation for the previous observations The major progress came from fine biosynthetic reporting strictly parallel variations of ACTH and studies using labelled amino acids incorporated into LPH plasma concentrations in a variety of pathological newly translated proteins combined with pulse-chase conditions (6). strategies. This approach was feasible in a cell line The final step was carried out by Numa’s group: which had a high rate of ACTH synthesis. The AtT-20 the cDNA of the mRNA coding for the precursor q 2003 Society of the European Journal of Endocrinology Online version via http://www.eje.org Downloaded from Bioscientifica.com at 09/30/2021 05:25:33AM via free access 80 M Raffin-Sanson and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 149 to ACTH was obtained and cloned (7). The sequence (NT). Exon 3 (833 bp) codes for most of the translated revealed – for the first time – the structure of the mRNA, i.e. the C-terminal part of the NT, joining ACTH precursor: ACTH itself was right in the middle, peptide (JP), ACTH, and bLPH (8, 9). Comparisons flanked by new sequences on its N-terminal end and between species show a strong homology between the by LPH on its C-terminal end. Thus the puzzle was ulti- DNA sequences coding for the NT, ACTH, bMSH and mately assembled, and established the molecular links bend, whereas the sequences coding for the JP and between ACTH, the LPHs, bend and putative new gLPH have poor homologies (10). peptides. The NT includes two intramolecular disulphide bridges, stabilising a loop structure composed of amphi- pathic amino acids. This conformational motif appears POMC expression and maturation in like a molecular sorting signal for POMC towards the human beings regulated secretory pathway (11). The POMC gene (Fig. 1) POMC gene expression in different tissues There is a single POMC gene per haploid genome (Fig. 2) in man. It is located on chromosome 2p23. It com- prises 7665 bp and consists of three exons and two POMC gene expression in the pituitary In normal introns. human pituitary, the POMC gene is only expressed in Exon 1 (87 bp) only contains untranslated corticotroph cells. Most mammals also possess an inter- sequences. Exon 2 (152 bp) codes for the signal peptide mediate lobe with POMC-expressing melanotroph cells and the first amino acids of the N-terminal peptide but this lobe is vestigial in adult man. Figure 1 POMC gene structure and expression. www.eje.org Downloaded from Bioscientifica.com at 09/30/2021 05:25:33AM via free access EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 149 Proopiomelanocortin: a multiple function polypeptide precursor 81 Figure 2 POMC gene expression in normal and tumoral tissues. In corticotroph cells, a mature POMC mRNA of 1072 transcript is found by Northern blot as well as the nucleotides (nt) is generated, after the splicing of the 1072 nt pituitary mRNA and sometimes a larger primary transcript and a poly A þ tail of ,200 nt is 1450 nt transcript. POMC mRNAs are produced at added. The 801 nt of the coding region are translated a low rate but the placental mass explains why this into a prePOMC molecule starting with a 26 amino expression can influence plasma concentration of acid signal peptide necessary for the translocation of POMC-derived peptides during pregnancy (see the nascent protein through the membrane of the further) (19, 20). rough endoplasmic reticulum (RER). The peptide More recently, POMC gene expression and the pro- signal is rapidly cleaved. The protein is then engaged duction of melanocyte-stimulating peptides have been into the secretory pathway: at that time, the 241 demonstrated in keratinocytes, melanocytes and amino acid POMC molecule is made of the peptides dermal microvascular endothelial cells, raising the NT, JP, ACTH and bLPH, and is ready for maturation possibility of an auto/paracrine role influencing skin (or processing). pigmentation. The baseline expression of the 1072 nt transcript is upregulated by ultraviolet radiation (21–23). POMC gene expression in non-pituitary tissues POMC mRNA has been reported by different groups in POMC processing (Fig. 3) many normal non-pituitary tissues, in animals and man. In most of these tissues, POMC gene expression is Once POMC has reached the lumen of the RER, it fol- quantitatively and qualitatively different from that in lows the intracellular traffic of secreted protein through the pituitary: the tissue concentration of POMC the Golgi apparatus and ultimately the secretory gran- mRNA is extremely low, and the generated mRNAs ules where the end-products of the processing are are essentially short, truncated, transcripts of stored before being secreted by exocytosis. During this ,800 nt. These transcripts result from heterogeneous traffic the POMC molecule undergoes a series of proteo- transcription initiation at the 50 end of exon 3 (12– lytic cleavages and chemical transformations, which 15). They are non-functional and cannot be efficiently altogether result in the maturation or processing of translated into POMC. the precursor, yielding the various biologically active In the brain, however, a well-defined population of POMC-derived peptides. neurons – in the arcuate nucleus – do express a POMC is a prototype polypeptide precursor which POMC mRNA that is identical to that in the pituitary contains eight pairs, and one quadruplet, of basic (16–18). In these neurons POMC is produced and amino acids, which are potential cleavage sites for serves as the precursor to cerebral bend, aMSH processing enzymes (Fig. 1). In a given tissue the and other peptides which have biological functions nature of the POMC end-products indicates which in the brain. Recently the MSH system has gained sites are cleaved in this particular tissue. Thus, in attention as its role in energy homeostasis emerged the corticotroph cells of the anterior pituitary, only (see below). four of these cleavage sites are used, which are all The placenta is another physiological site of of the Lys-Arg type. Indeed, the following six peptides POMC-derived peptide production. The short 800 nt are generated: NT, JP, ACTH, bLPH, and a small www.eje.org Downloaded from Bioscientifica.com at 09/30/2021 05:25:33AM via free access 82 M Raffin-Sanson and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003) 149 Figure 3 POMC processing by PC1 and PC2. amount of gLPH and bend, since the last cleavage acetylation of bend and aMSH). They contribute to site is only partially used (24–26).
Load more

Recommended publications
  • Actions of Vasoactive Intestinal Peptide on the Rat Adrenal Zona Glomerulosa
    51 Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa J P Hinson, J R Puddefoot and S Kapas1 Molecular and Cellular Biology Section, Division of Biomedical Sciences, St Bartholomew’s and The Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, Mile End Road, London E1 4NS, UK 1Oral Diseases Research Centre, St Bartholomew’s and The Royal London School of Medicine and Dentistry, 2 Newark Street, London E1 2AT, UK (Requests for offprints should be addressed to J P Hinson) Abstract Previous studies, by this group and others, have shown that The response to VIP in adrenals obtained from rats fed vasoactive intestinal peptide (VIP) stimulates aldosterone a low sodium diet was also investigated. Previous studies secretion, and that the actions of VIP on aldosterone have found that adrenals from animals on a low sodium secretion by the rat adrenal cortex are blocked by â diet exhibit increased responsiveness to VIP. Specific VIP adrenergic antagonists, suggesting that VIP may act by binding sites were identified, although the concentration the local release of catecholamines. The present studies or affinity of binding sites in the low sodium group was not were designed to test this hypothesis further, by measur- significantly different from the controls. In the low sodium ing catecholamine release by adrenal capsular tissue in group VIP was found to increase catecholamine release to response to VIP stimulation. the same extent as in the control group, however, in Using intact capsular tissue it was found that VIP caused contrast to the control group, the adrenal response to VIP a dose-dependent increase in aldosterone secretion, with a was not altered by adrenergic antagonists in the low concomitant increase in both adrenaline and noradrenaline sodium group.
    [Show full text]
  • Angiotensin II Protocol
    Angiotensin II (Giapreza ™) Protocol Background Sepsis and septic shock are medical emergencies that affect millions of people each year and killing as many as 1 in 4.1 The cornerstones of therapy are fluid resuscitation, early appropriate antibiotics, source control if needed and vasopressors. A small portion of patients fail to respond to these therapies and develop refractory shock. The definition of refractory septic shock varies in the literature but is generally considered to be hypotension, with end-organ dysfunction, requiring high-dose vasopressor support.2 The associated mortality of refractory septic shock is up to 60% and as high as 80-90% in patients requiring more than 1 mcg/kg/min of norepinephrine.2,3 Patients who develop refractory septic shock comprise a very small portion of the population in large randomized controlled trials therefore limited data is available regarding outcomes and management. Indications: Angiotensin II (Ang II) is a vasoconstrictor used to increase blood pressure in adults with septic or other distributive shock. Administration: Starting dose of 5 (nanograms) ng/kg/min intravenously via central line only. Titration: Every 5 minutes by increments of 5 ng/kg/min as needed. Maximum dose should not exceed 80 ng/kg/min (During the first 3 hours of administration); after the first 3 hours the maintenance (maximum) dose is 40 ng/kg/min. Monitoring: Critical care setting only with telemetry, arterial blood pressure, and continuous SpO2 monitoring. DVT Prophylaxis should be started (unless contraindicated)
    [Show full text]
  • Pulmonary Clearance of Vasoactive Intestinal Peptide
    Thorax: first published as 10.1136/thx.41.2.88 on 1 February 1986. Downloaded from Thorax 1986;41:88-93 Pulmonary clearance of vasoactive intestinal peptide MICHAEL P BARROWCLIFFE, ALYN MORICE, J GARETH JONES, PETER S SEVER From the Division ofAnaesthesia, Clinical Research Centre, Harrow, and the Department ofClinical Pharmacology and Therapeutics, St Mary's Hospital Medical School, London ABSTRACT Vasoactive intestinal peptide causes bronchodilatation when given intravenously but is less effective in both animals and man when given by inhalation. This difference may be due to poor transit of the peptide across the bronchial epithelium. To test this hypothesis pulmonary clearance of radiolabelled vasoactive intestinal peptide was measured in Sprague Dawley rats and compared with that of pertechnetate (Tc04 ) and diethylene triamine pentaacetate (DTPA). Despite a mole- cular weight (MW) of 3450, iodinated vasoactive intestinal peptide was cleared rapidly from the lungs, with a mean half time (t /2) of 19 minutes after an initial slower phase. This compares with a t'/2 of 10 minutes with Tc04 (MW 163) and a t1/2 of 158 minutes with DTPA (MW 492). The possibility that vasoactive intestinal peptide mediates a non-specific increase in permeability was discounted by the fact that the combination ofvasoactive intestinal peptide and DTPA did not alter DTPA clearance significantly. Chromatography and radioimmunoassay of blood taken after intra- tracheal administration of vasoactive intestinal peptide demonstrated a metabolite but no un- changed peptide. An intravenous injection ofthe peptide disappeared on first pass through the lung. copyright. It is concluded that inhaled vasoactive intestinal peptide lacks efficacy as a bronchodilator not because of slow diffusion to airway smooth muscle but because it is metabolised at an early stage of its passage through the respiratory epithelium.
    [Show full text]
  • Supplementary Table 1. Clinico-Pathologic Features of Patients with Pancreatic Neuroendocrine Tumors Associated with Cushing’S Syndrome
    Supplementary Table 1. Clinico-pathologic features of patients with pancreatic neuroendocrine tumors associated with Cushing’s syndrome. Review of the English/Spanish literature. Other hormones Age of Cortisol Other hormones Other ACTH Size (ICH or assay) ENETS Follow- Time Year Author Sex CS onset level (Blood syndromes or Site MET Type AH level (cm) corticotrophic Stage up (months) (years) (µg/dl) detection) NF other differentiation 1 1 1946 Crooke F 28 uk uk none no 4.5 H liver/peritoneum NET uk uk yes IV DOD 6 2 1956 Rosenberg 2 F 40 uk 92 none no 10 B liver NET uk uk yes IV PD 3 & p 3 1959 Balls F 36 uk elevated insulin Insulinoma 20 B liver/LNl/lung NET uk uk yes IV DOD 1 4 & 4 1962 Meador F 47 13~ elevated none no uk T liver/spleen NET ACTH uk yes IV uk 5 1963 Liddle5 uk uk uk elevated uk uk uk uk uk NET ACTH uk uk uk uk 6 1964 Hallwright6 F 32 uk uk none no large H LN/liver NET ACTH, MSH uk yes IV DOD 24 7 1965 Marks7 M 43 uk elevated insulin insulinomas 1.8 T liver NET uk uk yes IV DOD 7 8 1965 Sayle8 F 62 uk uk none carcinoidb 4 H LN/liver NET uk uk yes IV DOD 6 9 1965 Sayle8 F 15 uk uk none no 4 T no NET ACTH uk yes IIa DOD 5 9 b mesentery/ 10 1965 Geokas M 59 uk uk gastrin ZES large T NET uk uk yes IV DOD 2 LN/pleural/bone 11 1965 Law10 F 35 1.2 ∞ 91 gastrin ZESs uk B LN/liver NET ACTH, MSH gastrin yes IV PD 12 1967 Burkinshaw11 M 2 uk 72 none no large T no NET uk uk no uk AFD 12 13 1968 Uei12 F 9 uk uk none ZESs 7 T liver NET ACTH uk yes IV DOD 8 13 PTH, ADH, b gastrin, 14 1968 O'Neal F 52 13~ uk ZES uk T LN/liver/bone NET
    [Show full text]
  • Role of the Renin-Angiotensin-Aldosterone
    International Journal of Molecular Sciences Review Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension Natalia Muñoz-Durango 1,†, Cristóbal A. Fuentes 2,†, Andrés E. Castillo 2, Luis Martín González-Gómez 2, Andrea Vecchiola 2, Carlos E. Fardella 2,* and Alexis M. Kalergis 1,2,* 1 Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8330025 Santiago, Chile; [email protected] 2 Millenium Institute on Immunology and Immunotherapy, Departamento de Endocrinología, Escuela de Medicina, Pontificia Universidad Católica de Chile, 8330074 Santiago, Chile; [email protected] (C.A.F.); [email protected] (A.E.C.); [email protected] (L.M.G.-G.); [email protected] (A.V.) * Correspondence: [email protected] (C.E.F.); [email protected] (A.M.K.); Tel.: +56-223-543-813 (C.E.F.); +56-223-542-842 (A.M.K.) † These authors contributed equally in this manuscript. Academic Editor: Anastasia Susie Mihailidou Received: 24 March 2016; Accepted: 10 May 2016; Published: 23 June 2016 Abstract: Arterial hypertension is a common condition worldwide and an important predictor of several complicated diseases. Arterial hypertension can be triggered by many factors, including physiological, genetic, and lifestyle causes. Specifically, molecules of the renin-angiotensin-aldosterone system not only play important roles in the control of blood pressure, but they are also associated with the genesis of arterial hypertension, thus constituting a need for pharmacological interventions. Chronic high pressure generates mechanical damage along the vascular system, heart, and kidneys, which are the principal organs affected in this condition.
    [Show full text]
  • Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD
    International Journal of Molecular Sciences Review Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD Anastasia V. Poznyak 1,* , Dwaipayan Bharadwaj 2,3, Gauri Prasad 3, Andrey V. Grechko 4, Margarita A. Sazonova 5 and Alexander N. Orekhov 1,5,6,* 1 Institute for Atherosclerosis Research, Skolkovo Innovative Center, 121609 Moscow, Russia 2 Academy of Scientific and Innovative Research, CSIR-Institute of Genomics and Integrative Biology Campus, New Delhi 110067, India; [email protected] 3 Systems Genomics Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India; [email protected] 4 Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, 14-3 Solyanka Street, 109240 Moscow, Russia; [email protected] 5 Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia; [email protected] 6 Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia * Correspondence: [email protected] (A.V.P.); [email protected] (A.N.O.) Abstract: Atherosclerosis has complex pathogenesis, which involves at least three serious aspects: inflammation, lipid metabolism alterations, and endothelial injury. There are no effective treatment options, as well as preventive measures for atherosclerosis. However, this disease has various severe complications, the most severe of which is cardiovascular disease (CVD). It is important to note, that CVD is among the leading causes of death worldwide. The renin–angiotensin–aldosterone system (RAAS) is an important part of inflammatory response regulation. This system contributes to Citation: Poznyak, A.V.; Bharadwaj, the recruitment of inflammatory cells to the injured site and stimulates the production of various D.; Prasad, G.; Grechko, A.V.; cytokines, such as IL-6, TNF-a, and COX-2.
    [Show full text]
  • Preprocholecystokinin Processingin the Normal Human Anterior Pituitary
    Proc. Nati. Acad. Sci. USA Vol. 84, pp. 3019-3023, May 1987 Medical Sciences Preprocholecystokinin processing in the normal human anterior pituitary (cell differentiation/peptide hormone/radioimmunoassay) JENS F. REHFELD University Department of Clinical Chemistry, Rigshospitalet, DK-2100 Copenhagen, Denmark Communicated by Diter von Wettstein, January 2, 1987 (receivedfor review October 28, 1986) ABSTRACT The processing of preprocholecystokinin in (12). Two pituitary corticotrophic tumors from patients with human pituitary extracts was investigated using gel and ion- Nelson syndromes were obtained by transsphenoidal resec- exchange chromatography monitored by sequence-specific tion. The tumor specimens and the normal pituitary lobes radioimmunoassays before and after incubation with trypsin, were frozen in liquid nitrogen and stored at -80'C until carboxypeptidase B, and arylsulfatase. Whereas the neural extraction. The frozen tumors or lobes were minced (each lobe contained only the bioactive a-carboxyamidated cholecys- lobe separately), boiled for 20 min in redistilled water (pH tokinin (CCK) peptides (32 pmol/g), of which CCK-8 predom- 6.6, 10 ml/g of tissue), homogenized, and centrifuged. The inated, the anterior lobe contained substantial amounts ofthree pellet was extracted in an equal volume of 0.5 M CH3COOH large nonamidated procholecystokinin fragments (95 pmol/g; at 10°C and centrifuged; the supernatants were stored at Mrs, 9000, 7000, and 5000) and small amounts of a-amidated -20°C until analysis. The neutral and acid extracts diluted CCK (8.3 pmol/g). The latter occurred only in the following from 1:3 to 1:10,000 were assayed with sequence-specific large molecular forms: component I, CCK-58, and traces of CCK radioimmunoassays before and after treatment with CCK-33.
    [Show full text]
  • Glucocorticoids Exacerbate Obesity and Insulin Resistance in Neuron-Specific Proopiomelanocortin-Deficient Mice
    Amendment history: Corrigendum (March 2006) Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice James L. Smart, … , Virginie Tolle, Malcolm J. Low J Clin Invest. 2006;116(2):495-505. https://doi.org/10.1172/JCI25243. Research Article Endocrinology Null mutations of the proopiomelanocortin gene (Pomc–/–) cause obesity in humans and rodents, but the contributions of central versus pituitary POMC deficiency are not fully established. To elucidate these roles, we introduced a POMC transgene (Tg) that selectively restored peripheral melanocortin and corticosterone secretion in Pomc–/– mice. Rather than improving energy balance, the genetic replacement of pituitary POMC in Pomc–/–Tg+ mice aggravated their metabolic syndrome with increased caloric intake and feed efficiency, reduced oxygen consumption, increased subcutaneous, visceral, and hepatic fat, and severe insulin resistance. Pair-feeding of Pomc–/–Tg+ mice to the daily intake of lean controls normalized their rate of weight gain but did not abolish obesity, indicating that hyperphagia is a major but not sole determinant of the phenotype. Replacement of corticosterone in the drinking water of Pomc–/– mice recapitulated the hyperphagia, excess weight gain and fat accumulation, and hyperleptinemia characteristic of genetically rescued Pomc–/–Tg+ mice. These data demonstrate that CNS POMC peptides play a critical role in energy homeostasis that is not substituted by peripheral POMC. Restoration of pituitary POMC expression to create a de facto neuronal POMC deficiency exacerbated the development of obesity, largely via glucocorticoid modulation […] Find the latest version: https://jci.me/25243/pdf Research article Glucocorticoids exacerbate obesity and insulin resistance in neuron-specific proopiomelanocortin-deficient mice James L.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation
    biomedicines Review The Role of Corticotropin-Releasing Hormone at Peripheral Nociceptors: Implications for Pain Modulation Haiyan Zheng 1, Ji Yeon Lim 1, Jae Young Seong 1 and Sun Wook Hwang 1,2,* 1 Department of Biomedical Sciences, College of Medicine, Korea University, Seoul 02841, Korea; [email protected] (H.Z.); [email protected] (J.Y.L.); [email protected] (J.Y.S.) 2 Department of Physiology, College of Medicine, Korea University, Seoul 02841, Korea * Correspondence: [email protected]; Tel.: +82-2-2286-1204; Fax: +82-2-925-5492 Received: 12 November 2020; Accepted: 15 December 2020; Published: 17 December 2020 Abstract: Peripheral nociceptors and their synaptic partners utilize neuropeptides for signal transmission. Such communication tunes the excitatory and inhibitory function of nociceptor-based circuits, eventually contributing to pain modulation. Corticotropin-releasing hormone (CRH) is the initiator hormone for the conventional hypothalamic-pituitary-adrenal axis, preparing our body for stress insults. Although knowledge of the expression and functional profiles of CRH and its receptors and the outcomes of their interactions has been actively accumulating for many brain regions, those for nociceptors are still under gradual investigation. Currently, based on the evidence of their expressions in nociceptors and their neighboring components, several hypotheses for possible pain modulations are emerging. Here we overview the historical attention to CRH and its receptors on the peripheral nociception and the recent increases in information regarding their roles in tuning pain signals. We also briefly contemplate the possibility that the stress-response paradigm can be locally intrapolated into intercellular communication that is driven by nociceptor neurons.
    [Show full text]
  • Secretion, Degradation, and Elimination of Glucagon-Like
    Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Juris J. Meier,1 Michael A. Nauck,1,2 Daniel Kranz,1 Jens J. Holst,3 Carolyn F. Deacon,3 Dirk Gaeckler,4 Wolfgang E. Schmidt,1 and Baptist Gallwitz1 CRI patients vs. healthy control subjects, respectively. ؎ ؎ Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the patho- Plasma half-lives of intact GIP were 6.9 1.4 and 5.0 ؎ ؎ ؍ genesis of type 2 diabetes and have a promising thera- 1.2 min (P 0.31) and 38.1 6.0 and 22.4 3.0 min for ؍ peutic potential. Alterations of their secretion, in vivo the GIP metabolite (P 0.032) for CRI patients vs. degradation, and elimination in patients with chronic healthy control subjects, respectively. Insulin concen- renal insufficiency (CRI) have not yet been character- trations tended to be lower in the patients during all ized. Ten patients with CRI (aged 47 ؎ 15 years, BMI experiments, whereas C-peptide levels tended to be kg/m2, and serum creatinine 2.18 ؎ 0.86 elevated. These data underline the importance of the 2.2 ؎ 24.5 mg/dl) and 10 matched healthy control subjects (aged kidneys for the final elimination of GIP and GLP-1. The years, BMI 24.9 ؎ 3.4 kg/m2, and serum creati- initial dipeptidyl peptidase IV–mediated degradation of 12 ؎ 44 nine 0.89 ؎ 0.10 mg/dl) were included. On separate both hormones is almost unaffected by impairments in occasions, an oral glucose tolerance test (75 g), an renal function.
    [Show full text]
  • Proopiomelanocortin, a Polypeptide Precursor with Multiple Functions
    European Journal of Endocrinology (2003) 149 79–90 ISSN 0804-4643 INVITED REVIEW Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions M L Raffin-Sanson1,3, Y de Keyzer1 and X Bertagna1,2 1Institut Cochin, De´partement d’Endocrinologie, Universite´ Rene´ Descartes-Paris V, France, 2Service des Maladies Endocriniennes et Me´taboliques, Hoˆpital Cochin, Paris, France and 3Me´decine Interne 2, Endocrinologie, Hoˆpital Ambroise Pare´, Boulogne/S, France (Correspondence should be addressed to X Bertagna; Email: [email protected]) Abstract Proopiomelanocortin (POMC) is the polypeptide precursor of ACTH. First discovered in anterior pitu- itary corticotroph cells, it has more recently been revealed to have many other physiological aspects. The fine molecular mechanisms of ACTH biosynthesis show that ACTH is but one piece of a puzzle which contains many other peptides. Present in various tissues, among which are pituitary, hypo- thalamus, central nervous system and skin, POMC undergoes extensive post-translational processing. This processing is tissue-specific and generates, depending on the case, various sets of peptides involved in completely diverse biological functions. POMC expressed in corticotroph cells of the pitu- itary is necessary for adrenal function. Recent developments have shown that POMC-expressing neur- ons in the brain play a major role in the control of pain and energy homeostasis. Local production of POMC-derived peptides in skin may influence melanogenesis. A still unknown function in the placenta is likely. POMC has become a paradigmatic polypeptide precursor model illustrating the variable roles of a single gene and its various products in different localities.
    [Show full text]